Bacda-B

Each gram of cream contains Clotrimazole (Bacda-B) 10 mg (1%) and Betamethasone (Bacda-B) dipropionate 0.64 mg, equivalent to Betamethasone (Bacda-B) 0.5 mg (0.05%) in a smooth, uniform, white to off-white cream, free from foreign matter. It also contains the following inactive ingredients: Mineral oil, white petrolatum, cetostearyl alcohol, polyethylene glycol 1000 monocetylether, benzyl alcohol, sodium phosphate monobasic dihydrate, phosphoric acid, sodium hydroxide, propylene glycol, purified water and benzyl alcohol 10 mg/g (preservative).

indicated for the relief of the inflammatory manifestations of corticosteroid responsive dematoses when complicated by secondary fungal infection Indicated (as a secondary agent) in the topical treatment of tinea corporis (ringworm of the body), tinea cruris (jock itch; ringworm of the groin), and tinea pedis (athlete

Clotrimazole (Bacda-B) and Betamethasone (Bacda-B) topical combination is used to treat fungus infections. Clotrimazole (Bacda-B) works by killing the fungus or preventing its growth. Betamethasone (Bacda-B), a corticosteroid (cortisone-like medicine or steroid), is used to help relieve redness, swelling, itching, and other discomfort of fungus infections.

Clotrimazole (Bacda-B) and Betamethasone (Bacda-B) topical cream or lotion is applied to the skin to treat:

• Ringworm of the foot (tinea pedis; athlete's foot);
• Ringworm of the groin (tinea cruris; jock itch); and
• Ringworm of the body (tinea corporis).

This medicine is available only with your doctor's prescription.

Gently massage sufficient Bacda-B cream into the affected and surrounding skin areas twice a day, in the morning and evening, for 2 weeks in tinea cruris, tinea corporis and candidiasis, and for 4 weeks in tinea pedis.

Duration of Therapy: Clinical improvement, with relief of erythema and pruritus, usually occurs within the first 3-5 days of treatment. If a patient with tinea cruris, tinea corporis or candidiasis shows no clinical improvement after 1 week of treatment with Bacda-B, the diagnosis should be reviewed. In tinea pedis, the treatment should be applied for 2 weeks prior to making that decision.

If the condition persists after 2 weeks in tinea cruris and tinea corporis, and after 4 weeks in tinea pedis, treatment with Bacda-B should be discontinued. Alternate therapy may then be instituted with an appropriate antifungal agent only. The use of Bacda-B for >4 weeks is not recommended.

Patients with a history of sensitivity reactions to any of the components of Bacda-B or to other corticosteroids or imidazoles.

gently massaged into the affected skin and surrounding area in the morning and evening. The treated skin should not be bandaged, covered, or wrapped in order to avoid excessive absorption of Lotrisone into the body.

cream or lotion should not be used for more than 2 weeks for treatment of tinea corporis or tinea cruris. If there is no clinical improvement after one week of treatment, the diagnosis should be reviewed.

should not be used longer than 4 weeks for treatment of tinea pedis. If there is no clinical improvement after 2 weeks of treatment, the diagnosis should be reviewed.

See also:
What are the possible side effects of Bacda-B?

Those Indicating Need for Medical Attention: Incidence Less Frequent or Rare: Allergic contact dermatitis (burning and itching of skin; apparent chronic therapeutic failure). May also be caused by vehicle ingredients; folliculitis, furunculosis, pustules, pyoderma, or vesiculation (painful, red or itchy, pus-containing blisters in hair follicles), more frequent with occlusion or use of ointments in intertriginous areas; hyperesthesia (increased skin sensitivity); numbness in fingers; purpura (blood-containing blisters on skin); skin atrophy (thinning of skin with easy bruising, especially when used on facial or intertriginous area); skin infection, secondary - more frequent with occlusion; stripping of epidermal layer- for tape dosage forms; telangiectasis (raises, dark red, wart-like spots on skin, especially when used on the face).

Rare Incidence: With prolonged use or other factors that increase absorption. Acneiform eruptions (acne or oily skin, especially when used on the face); cataracts, posterior subcapsular (gradual blurring or loss of vision)- reported with use of systemic corticosteroids; caution is advised with use of high- and very high-potency topical corticosteroids in periorbital area; cushing's syndrome (backache; filling or rounding out of the face; irritability; menstrual irregularities; mental depressions; in men, unusual decrease in sexual desire or ability; unusual tiredness or weakness); dermatitis, prioral (irritation of skin around mouth); ecchymosis (unusual bruising); edema (increased blood pressure; rapid weight; swelling of feet or lower legs); gastric ulcer (loss of appetite; nausea; stomach bloating, burning, cramping, or pain; vomiting; weight loss); secondary glaucoma (eye pain; gradual decrease in vision; nausea; vomiting)- with use of high- and very high-potency topical corticosteroids in peritoneal area; hirsutism or hypertrichosis (unusual increase in hair growth, especially on the face); hypertension; hypokalemia syndrome (irregular heartbeat; loss of appetite; muscle cramps or pain; nausea; severe weakness of extremities and trunk; vomiting); hypopigmentation (lightened skin color); or other changes in skin pigmentation; aggravation of infection; miliaria rubra (burning and itching of skin with pinhead-sized red blisters); protein depletion (muscle weakness); skin laceration (tearing of skin); skin maceration (softening of skin); striae (reddish purple lines on arms, face, legs, trunk or groin); SC tissue atrophy; unusual loss of hair especially on the scalp.

Those indicating need for medical attention only if they continue or are bothersome: Less Frequent or Rare Incidence: Burning, dryness, irritation, itching or redness of skin, mild and transient; increased redness or scaling of skin lesions, mild and transient; skin rash, minor and transient.

Those Not Indicating Need for Medical Attention Only if They Continue or are Bothersome: Stinging, mild and temporary when foam, gel, lotion, solution or aerosol form of medication is applied.